58 results about "Superparamagnetic iron oxide nanoparticle" patented technology

The injectable formulation for treatment by hyperthermia comprises a liquid carrier and heat-generating superparamagnetic iron oxide nanoparticles having a mean diameter not greater than 20 nm. Said injectable formulation is able to form in-situ a hyperthermic solid or semi-solid implant upon contact with a body fluid or tissue. Said hyperthermic solid or semi-solid implant may be useful for treating a tumor or a degenerative disc disease by hyperthermia.

The invention discloses a Fe3O4@SiO2@P4VP-PDMS-P4VP hybrid nanoparticle with pH and magnetic responsiveness and a preparation method thereof and an application of the hybrid nanoparticle in a nano oil-water separation emulsion. The Fe3O4@SiO2@P4VP-PDMS-P4VP hybrid nanoparticle is obtained by coupling reaction of a pyridine group on a P4VP block in a P4VP-PDMS-P4VP triblock copolymer with pH responsiveness with a C-I active group on the superparamagnetic iron oxide nanoparticles Fe3O4@SiO2 surface and bonding the P4VP-PDMS-P4VP triblock copolymer into the Fe3O4@SiO2 nanoparticle surface. The invention further specifically discloses the preparation method of the Fe3O4@SiO2@P4VP-PDMS-P4VP hybrid nanoparticle and the application of the Fe3O4@SiO2@P4VP-PDMS-P4VP hybrid nanoparticle in the nano oil-water separation emulsion. Due to the action of the central Fe3O4magnetic nanoparticle, the hybrid nanoparticle absorbing oil content can be easily separated from an aqueous system, and the oil absorbed hybrid nanoparticle can be recycled in an acid aqueous solution after absorption.

The invention relates to a preparation method of RGD-modified subminiature superparamagnetic iron oxide nanoparticles. The preparation method comprises the following steps of preparing PEI-coated subminiature superparamagnetic iron oxide nanoparticles by a mild reduction method, modifying surfaces of USPIO/PEI.NH2 nanoparticles by fluorescein isothiocyanate (FI) and a RGD compound (COOH-PEG-RGD) subjected to pegylation, and carrying out acetylation treatment on the surfaces of the nanoparticles. The preparation method has simple processes and mild reaction conditions and can be operated easily. The RGD-modified subminiature superparamagnetic iron oxide nanoparticles have small sizes, a high relaxation rate, good colloid stability and biocompatibility, and high alpha<v>beta<3> integrin high-expression tumor cell targeting, and have a latent application value in the field of in-vivo tumor targeting MR imaging diagnosis.

The various embodiments herein provide for the engineered multimodal super paramagnetic iron oxide nanoparticles (SPIONs) with a fluorescent dye. The SPIONs comprise fluorescent polymer dye arranged in a gap between a SPION core and a gold shell. The SPIONS are provided with a gold coating. The gap is made up of a polymeric molecule such as 6-arm anthracene terminated. The core of the nanoparticle is made up of a magnetic metal oxide. The method for synthesizing SPIONs involves preparing carboxyl-dextran complex and the SPIONS. The SPIONs are coated with carboxyl-dextran complex. The coated SPIONs coated are subjected to fluorescent polymer and gold nano shell coating. The prepared SPIONs are characterized by light scattering measurement and magnetization measurements.

Erythrocytes exposed to dialysis with an hypotonic buffer stably take up superparamagnetic iron oxide nanoparticles and may be used MRI contrast agents. Such erythrocytes may also be used as drug delivery vehicles.

Silica nanocarriers hybridized with superparamagnetic iron oxide nanoparticles (“SPIONs”) and curcumin through equilibrium or enforced adsorption technique. Methods for dual delivery of SPIONs and curcumin to a target for diagnosis or therapy, for example, for SPION-based magnetic resonance imaging or for targeted delivery of curcumin to a cell or tissue. The technique can be extend to co-precipitation of mixed metal oxide involving Ni, Mn, Co and Cu oxide. The calcination temperature can be varied from 500-900° C. The nanocombination is functionalized with chitosan, polyacrylic acid, PLGA or another agent to increase its biocompatibility in vivo.

The invention discloses a preparation method for a high-sensitivity bimodal magnetic resonance contrast agent. According to the preparation method, by means of a method for preparing ferric oleate andmanganese chloride through thermal decomposition, a high-boiling-point solvent is adopted as a reaction medium, oleic acid and oleylamine are used as stabilizers, and therefore manganese oxide embedded iron oxide nanoparticles with narrow particle size distribution and high degree of crystallinity are obtained. The invention particularly relates to a preparation method for modifying the manganeseoxide embedded iron oxide nanoparticles by utilizing the oleic acid/the oleamine, or a preparation method for the biocompatible and water-soluble manganese oxide embedded iron oxide nanoparticles. The preparation method for the high-sensitivity dual-mode magnetic resonance contrast agent has the advantages that the requirements of magnetic resonance imaging for the contrast agent and the characteristics of the Nanotechnology are combined, by means of regulation and control over chemical synthesis, manganese oxide with the T1 contrast capability and superparamagnetic iron oxide nanoparticles with the T2 contrast capability are combined so as to form the manganese oxide embedded iron oxide nanoparticles, and therefore the cooperatively-enhancing dual-mode magnetic resonance contrast effectcan be achieved between the two imaging modes, namely, the T1 imaging mode and the T2 imaging mode.

Bioconjugates and methods of making bioconjugates are provided, wherein the bioconjugates comprise glucose oxidase and nanoparticles that can kill tumor cells. For example, glucose oxidase-iron oxide bioconjugates can produce reactive oxygen species from blood glucose, causing cell death. The use of superparamagnetic iron oxide nanoparticles can provide magnetic resonance imaging guidance to facilitate imaging-guided drug delivery and combine diagnostics with therapy.

The present invention discloses biocompatible, stable curcumin or its derivatives coated ultra-small super paramagnetic iron oxide nanoparticles (USPION) for biomedical applications. Disclosed herein is also a simple one-pot process for the synthesis of biocompatible, stable curcumin or its derivatives coated ultra-small superparamagnetic iron oxide nanoparticles in absence of a linker or binder. The curcumin or its derivatives coated ultra-small super paramagnetic iron oxide nanoparticles of the present invention retains the medicinal, radical scavenging and fluorescence properties of curcumin.

The invention provides a T1-T2 double-activated magnetic resonance imaging contrast agent as well as a preparation method and application thereof. The T1-T2 double-activated magnetic resonance imagingcontrast agent has a core-shell structure and sequentially comprises T2 contrast agent nanoparticles, a silicon dioxide layer, a T1 contrast agent layer and a modification layer from inside to outside, and the T2 contrast agent nanoparticles are superparamagnetic iron oxide nanoparticles. The T1-T2 double-activated magnetic resonance imaging contrast agent is in a T1 and T2 contrast agent signaldouble-quenching state in normal tissues around an in-vivo tumor, and T1 and T2 contrast agent signals can be activated at the same time at a tumor part, so that the tumor part and the surrounding normal tissues have a remarkable MRI signal difference, and the T1-T2 double-activated magnetic resonance imaging contrast agent has targeting property on tumor cells, so as to realize high-quality imaging for the tumor part.

The invention provides application of a superparamagnetic iron oxide nanoparticle applied in a transdermal drug delivery system. The superparamagnetic iron oxide nanoparticle is taken as a drug carrier of epirubicin; an epirubicin-superparamagnetic iron oxide nanoparticle transdermal drug delivery system is prepared; and a primary amine group (-NH2) exists on the surface of the superparamagnetic iron oxide nanoparticle. The superparamagnetic iron oxide nanoparticle can achieve transdermal absorption and has no poison, stimulation or anaphylactic reaction to skins, and the defects that a superparamagnetic iron oxide nanoparticle is single in drug-delivery manner and the magnetic field implementation is limited are overcome.

The invention provides an aptamer target-based superparamagnetic iron oxide nanocomposite magnatic resonance imaging contrast agent. The aptamer target-based superparamagnetic iron oxide nanocomposite magnatic resonance imaging contrast agent comprises the following components: (a) oligonucleotides or peptide aptamers for molecular recognition; (b) superparamagneticiron oxide nanoparticles; and (c) a biocompatible amphiphilic dextran block copolymer carrier, which is used for connecting the superparamagneticiron oxide nanoparticles and the oligonucleotides or peptide aptamers for molecular recognition. The aptamers, the superparamagnetic iron oxide nanoparticles and a block copolymer of polyethylene glycol, polycaprolactone and polysaccharide are assembled into a nanomicelles complex; through the targeting effect of specifically bounding the aptamers and a target molecule and magnetic resonance imaging features of SPIO nanoparticles, the complex nanomicelles is established by the biocompatible block copolymer; and after the aptamer target-based superparamagnetic iron oxide nanocomposite magnatic resonance imaging contrast agent enters a body, small foci are positioned in a targeting way so as to realize early targeting positioning and diagnosis of the small foci in vitro and in vivo through the conventional magnetic resonance imaging diagnostic equipment. By selecting a proper target molecule aptamer, the aptamer target-based superparamagnetic iron oxide nanocomposite magnatic resonance imaging contrast agent can be applied to cell signaling, metabolic process, gene detection, virus detection, tumor detection and other biological researches.

The invention discloses a magnetic-field-point-free magnetic nanoparticle imaging method based on a hysteresis effect. The method comprises the following steps: obtaining a hysteresis loop model of a superparamagnetic nanoparticle (Superparamagnetic Iron Oxide Nanoparticles, SPIO); carrying out calculating based on a sine excitation magnetic field and the hysteresis loop model of the SPIO, so as to obtain a point spread function (PSF) of the SPIO; acquiring an original reconstructed image of field free point-magnet particle imaging (FFP-MPI) based on a field free point (FFP) moving track and a voltage signal; and carrying out deconvolution on the PSF considering the hysteresis effect of the original image, thereby obtaining a final reconstructed image. According to the method, artifacts and phase errors generated by the hysteresis effect of the large-particle-size SPIO on image reconstruction are reduced, the defect of the traditional reconstruction method that reconstruction is carried out by ignoring the hysteresis effect is overcome, the reconstruction speed and resolution are greatly improved, and the application range of the SPIO is widened.

A multi-functional drug composition capable of pH responsive drug release comprising siliceous nanoparticles having three dimensional cage structures type silica with thick pore walls and mesosilicalite, superparamagnetic iron oxide nanoparticles (SPION) and pharmaceutical composition thereof is disclosed. The drug delivery system is useful for targeting a drug to particular diseased tissues such as cancerous tissues.

The invention relates to the technical field of drug carriers, in particular to a magnetic nano-drug carrier as well as a preparation method and an application thereof. The magnetic nano-drug carrier comprises an SP94 targeting peptide and a coupling product of an siRNA delivery carrier, and the coupling product of the siRNA delivery carrier comprises superparamagnetic iron oxide nanoparticles and quaternary ammonium cationized amylose-tetraphenylethylene-superparamagnetic iron oxide nanoparticles formed by coupling quaternary ammonium cationized amylose and tetraphenylethylene, and the siRNA is adsorbed in the magnetic nano-drug carrier. The cytotoxicity experiments prove that the nano-drug carrier has good biocompatibility, good stability, targeting property and drug release property, and the magnetic nano-drug carrier can be applied to preparation of cancer gene therapy drugs.

The invention provides a medical nano composite including (a) an oligonucleotides or peptide aptamer for molecular identification; (b) a superparamagnetic iron oxide nanoparticle; and (c) a biocompatible amphiphilic glucan block copolymer carrier used for the superparamagnetic iron oxide nanoparticle and connecting the oligonucleotides or peptide aptamer for molecular identification. The medical nano composite is assembled by use of the aptamer, the superparamagnetic iron oxide nanoparticle, and a polyethylene glycol, polycaprolactone and polysaccharide block copolymer, by use of the targeting effect of specific binding of the aptamer and a target molecule and magnetic resonance imaging (mri) features of the superparamagnetic iron oxide (SPIO) nanoparticle, composite nano micelle is constructed by a biocompatible block copolymer, enters the body for target positioning of small disease focus, and is used for early target positioning diagnosis of minimal lesion in vitro and vivo by use of conventional nuclear magnetic resonance imaging diagnostic equipment. By choosing of an appropriate target molecule aptamer, the medical nano composite also can be used in cell signaling, metabolic process, gene detection, virus detection, tumor detection and other bioresearches.